H.C. Wainwright Initiates ProMIS Neurosciences with Buy Rating, $4 Price Target

H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of ProMIS Neurosciences with a Buy rating and $4 price target. The biotechnology company focuses on developing therapeutic and vaccine-based approaches for serious unmet medical needs in neurology.

July 2, 2025 - H.C. Wainwright analyst Raghuram Selvaraju has initiated coverage of ProMIS Neurosciences (NasdaqCM: PMN) with a Buy rating and a price target of $4 per share [1]. The biotechnology company specializes in developing therapeutic and vaccine-based solutions for critical neurological health challenges.

According to Selvaraju, ProMIS Neurosciences' focus on addressing significant unmet needs within the neurology field positions it as a promising investment opportunity. The analyst highlighted the company's neurodegenerative pipeline, which includes therapies targeting critical conditions such as Alzheimer’s and Parkinson’s [2].

The initiation of coverage by H.C. Wainwright has sparked optimism among investors, leading to a significant intraday surge in ProMIS Neurosciences' stock price. On July 14, 2025, the stock surged 67% to $0.6526, reaching a peak of $1.25 before closing at $0.6526 [3]. This surge was driven by the analyst's Buy rating and price target, which represents a 1,351% upside from the current levels.

The average one-year price target for ProMIS Neurosciences is $5.78 per share, with forecasts ranging from $3.03 to $8.40 [1]. This represents a substantial increase from the latest reported closing price of $0.39 per share, indicating significant potential for growth.

While the broader biotech sector has shown mixed resilience to regulatory headwinds, ProMIS Neurosciences stands out as a leader in the high-growth area of neurodegenerative therapies. The company's focus on critical neurological conditions differentiates it from peers facing FDA pushback in other therapeutic areas [3].

Technical indicators suggest that the stock may be overextended, with the Relative Strength Index (RSI) indicating deep oversold conditions and Bollinger Bands showing trading 33% above the 30-day average [3]. Bulls face critical resistance at the $1.25 intraday high, while key support lies near the 52-week low of $0.60. Aggressive investors may consider layering in on dips toward the 200-day average at $0.55.

ProMIS Neurosciences' stock performance after its intraday surge shows mixed results in backtesting. While the 3-day win rate is relatively high at 43.64%, returns over 10 and 30 days are negative, suggesting short-term volatility following a significant intraday gain [3].

Investors should prioritize profit-taking above $0.80 while monitoring broader biotech sentiment, as indicated by sector leader Amgen’s (AMGN) 0.13% gains. This volatile session underscores the high-risk, high-reward nature of early-stage biotechs, emphasizing the importance of disciplined investing as clinical data looms.

References:
[1] https://fintel.io/news/hc-wainwright-co-initiates-coverage-of-promis-neurosciences-pmn-with-buy-recommendation-654
[2] https://www.gurufocus.com/news/2973969/promis-neurosciences-pmn-gains-analyst-support-with-buy-rating-pmn-stock-news
[3] https://www.ainvest.com/news/promis-neurosciences-rockets-67-fueling-biotech-breakout-2507/